BioMarin Pharma (BMRN) Tops Q3 EPS by 38c; raises guidance
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $64.78 -0.46%
EPS Growth %: +1,016.7%
Financial Fact:
Interest expense: -9.98M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +1,016.7%
Financial Fact:
Interest expense: -9.98M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of $0.91, $0.38 better than the analyst estimate of $0.53. Revenue for the quarter came in at $746 million versus the consensus estimate of $703.14 million.
GUIDANCE:
BioMarin Pharma sees FY2024 EPS of $3.25-$3.35, versus the consensus of $3.22. BioMarin Pharma sees FY2024 revenue of $2.79-2.825 billion, versus the consensus of $2.799 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Downgrades Nucor (NUE) to Hold, 'Guides Conservative Earnings Yet Again'
- EMA panel backs Novartis Cosentyx for rheumatic condition in EU
- Lumentum shares rise on analyst upgrades, AI demand outlook
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
